Biotech Values

[jbog]

ghmm

Here's one of the write-ups I saw on Patheon. You'll see they're not a start-up company. I've dealt with them for years.

Summary:

Patheon N.V. plans to raise $625 million in its IPO that is scheduled for July 21, 2017.

The company will sell 30.5 million shares at a price range of $19 to $22.

The company boasts a roster of powerful underwriters and has manufactured and developed 92 new drugs in the past 10 years.

Patheon generated $1.8 billion in revenues in the past 12 months and has strong financials.

We look forward to the IPO and strongly suggest investors buy shares.

Patheon N.V. (NYSE: PTHN) (ticker symbol pending) plans to raise up to $625 million in its IPO that is scheduled for July 21, 2017. The company is offering 30.5 million shares at a price range of $19.00 to $22.00 per share. The underwriters will have the option to purchase up to 4,573,171 additional shares. The underwriters for the offering include Credit Suisse, Jeffries, J.P. Morgan, Morgan Stanley, UBS Investment Bank, Wells Fargo Securities, Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners.

Business summary

Patheon N.V. provides outsourced manufacturing and pharmaceutical development services globally. The company is one of the largest contract drug manufacturers and is based in Amsterdam. According to its SEC filings, it is the only company worldwide that provides end-to-end integrated services, allowing the company to offer a comprehensive suite to its customers in order to address all of their development and drug manufacturing needs. Patheon supports across all stages of drug development, from created the drug formulations and active ingredients, to providing large-scale manufacturing and packaging.

Executive management overview

James Mullen has served as the CEO of Patheon since joining the company in 2011. During his tenure, he has led Patheon through its acquisition of Banner Pharmacaps in 2012 and in the merger of Patheon with DSM Pharmaceutical Products in 2013. Prior to joining Patheon, Mullen previously served as the CEO of Biogen Idec Inc. Other positions he held at Biogen included: Chairman, CEO and president of Biogen before its merger with Idec was finished. Mullen has more than 30 years of pharmaceutical and executive management experience and previously served the Biotechnology Industry Organization as its chairman. He earned his Bachelor of Science in chemical engineering at the Rensselaer Polytechnic Institute and completed his Master of Business Administration at Villanova University.

http://seekingalpha.com/article/3989370-patheon-ipo-pay-deal-price-wednesday